Celgene (CELG) Said to Acquire Swiss Biotech in $600M Deal

September 30, 2016 11:06 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Celgene (Nasdaq: CELG) said to acquire Swiss biotech EngMab in a deal valued at $600 million, according to Endpoints News. The site said it confirmed the deal with a Celgene rep.

The deal would add a BMCA-targeting multiple myeloma program pipeline into Celgene's coffers.

The Celgene rep was said to comment: B-cell maturation antigen (BCMA) is highly and selectively expressed on the surface of malignant plasma cells in MM and target of high value for immune based therapies such as re-engineered autologous T-CAR-T and the re-direction of CD4+ and CD8+ T lymphocytes via anti-CD3 bi-specific antibodies.

Shares of Celgene are up 1.5 percent Friday mroning

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Mergers and Acquisitions, Rumors

Related Entities

Definitive Agreement

Add Your Comment